Trademark Overview
On Monday, December 15, 2025, a trademark application was filed for ARATECAN with the United States Patent and Trademark Office. The USPTO has given the ARATECAN trademark a serial number of 79448735. The federal status of this trademark filing is NEW APPLICATION - ASSIGNED TO EXAMINER as of Saturday, April 25, 2026. This trademark is owned by Araris Biotech AG. The ARATECAN trademark is filed in the Chemical Products, Pharmaceutical Products, Advertising, Business and Retail Services, and Computer & Software Services & Scientific Services categories with the following description:
Peptides, peptide derivatives, proteins, glycans, lipids, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors for scientific use; chemical, biological, biotechnological and molecular genetic preparations, namely polypeptides and proteins for reagent development or production for industrial and scientific applications; biological preparations, namely, polypeptides, peptide derivatives for laboratories and analysis for industrial and scientific applications; chemical and biochemical substances for manufacturing pharmaceutical products.
Provision of information with respect to business contacts for research projects.
Scientific, medical, biological, molecular genetic, chemical, pharmaceutical and technological research, in the field of biochemistry or pharmacy; biochemical or pharmaceutical laboratory services; industrial analysis and research services; development and experimentation of medicines; conducting preclinical and clinical trials; laboratory services for the benefit of third parties; scientific advisory services in the biochemical, biological and molecular genetic fields; scientific advice for the pharmaceutical industry sector; analysis services for medical and pharmaceutical research services in connection with the treatment of individuals, included in class 42; provision of scientific research information and results.
Pharmaceutical products and medical preparations in the field of cancer therapy; biopharmaceuticals and medical preparations in the field of active antibody conjugates; chemical, biological, molecular and biochemical genetic and biopharmaceutical products for medical and pharmaceutical use, namely peptides, peptide derivatives, active principle antibody conjugates, antibody fragments, antibody derivatives, vectors; pharmaceutical products and substances for disease treatment and preparations for medical treatments.
